阿达木单抗治疗非感染性中间、后或全葡萄膜炎的长期安全性与疗效
VISUAL III 开放标签扩展研究评估阿达木单抗 40 mg 隔周皮下注射治疗非感染性中间、后或全葡萄膜炎的长期疗效与安全性,数据收集至 362 周。入组时 67% 患者为活动性葡萄膜炎,33% 为非活动性;至第 150 周,达到静止的患者比例从 34% 升至 85%,全身糖皮质激素日均剂量从 9.4 mg 降至 1.5 mg。感染是最常见的不良事件,安全性与母试验一致。
要点
- 阿达木单抗长期治疗可使活动性葡萄膜炎患者达到静止并减少激素用量。
- 入组时非活动性患者维持静止状态。
- 最常见治疗中出现的不良事件为感染,安全性与已知特征一致。
核心结论
- 长期阿达木单抗治疗使入组 VISUAL III 时的活动性葡萄膜炎患者达到静止并减少糖皮质激素使用。
- 对入组时非活动性葡萄膜炎患者维持了静止状态。
- 不良事件与母试验报告相当,并与阿达木单抗已知安全性特征一致。
研究设计与样本
- 开放标签、多中心、3 期扩展研究(VISUAL III)。
- 纳入完成随机安慰剂对照 3 期母试验(VISUAL I 或 II)且未治疗失败(非活动性葡萄膜炎)或符合治疗失败标准后退出研究(活动性葡萄膜炎)的成人患者。
- 患者接受阿达木单抗 40 mg 隔周皮下注射,数据收集至 362 周。
- 不良事件记录至末次给药后 70 天。
主要发现
- 研究入组时 67%(283/424)患者为活动性葡萄膜炎,33%(141/424)为非活动性。
- 60 例患者后续符合排除标准,364 例纳入意向性治疗分析。
- 疗效变量分析至第 150 周,此时约 50%(214/424)患者仍在研究中。
- 达到静止的患者比例从第 0 周的 34%(122/364)增至第 150 周的 85%(153/180)。
- 入组时活动性或非活动性葡萄膜炎患者分别有 54%(66/123)和 89%(51/57)达到无糖皮质激素的静止。
临床怎么用
- 对于非感染性中间、后或全葡萄膜炎成人患者,可考虑阿达木单抗 40 mg 隔周皮下注射长期治疗以控制炎症并减少激素用量。
- 治疗期间需监测感染等不良事件,其发生率与已知安全性特征一致。
局限性
- 为开放标签扩展研究,无安慰剂对照。
- 疗效变量分析至第 150 周,约半数患者仍在研究。
- 数据收集至 362 周,但主要疗效分析截止于第 150 周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Open-label, multicenter, phase 3 extension study (VISUAL III). PARTICIPANTS: Adults who had completed a randomized, placebo-controlled phase 3 parent trial (VISUAL I or II) without treatment failure (inactive uveitis) or who discontinued the study after meeting treatment failure criteria (active uveitis). METHODS: Patients received subcutaneous adalimumab 40 mg every other week. Data were collected for ≤ 362 weeks. Adverse events (AEs) were recorded until 70 days after the last dose. MAIN OUTCOME MEASURES: Long-term safety and quiescence; other efficacy variables included inflammatory lesions, anterior chamber cell and vitreous haze grade, macular edema, visual acuity, and dose of uveitis-related systemic corticosteroids. RESULTS: At study entry, 67% of patients (283/424) showed active uveitis and 33% (141/424) showed inactive uveitis; 60 patients subsequently met exclusion criteria, and 364 were included in the intention-to-treat analysis. Efficacy variables were analyzed through week 150, when approximately 50% of patients (214/424) remained in the study. Patients showing quiescence increased from 34% (122/364) at week 0 to 85% (153/180) at week 150. Corticosteroid-free quiescence was achieved by 54% (66/123) and 89% (51/57) of patients with active or inactive uveitis at study entry. Mean daily dose of systemic corticosteroids was reduced from 9.4 ± 17.1 mg/day at week 0 (n = 359) to 1.5 ± 3.9 mg/day at week 150 (n = 181). The percentage of patients who achieved other efficacy variables increased over time for those with active uveitis at study entry and was maintained for those with inactive uveitis. The most frequently reported treatment-emergent AEs of special interest were infections (n = 275; 79 events/100 patient-years [PY]); AEs and serious AEs occurred at a rate of 396 events/100 PY and 15 events/100 PY, respectively. CONCLUSIONS: Long-term treatment with adalimumab led to quiescence and reduced corticosteroid use for patients who entered VISUAL III with active uveitis and led to maintenance of quiescence for those with inactive uveitis. AEs were comparable with those reported in the parent trials and consistent with the known safety profile of adalimumab.
引用
- Suhler EB, Jaffe GJ, Fortin E, et al. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2020. PMID: 33157077. doi:10.1016/j.ophtha.2020.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。